Translator Disclaimer
26 October 2019 Viability and migratory effects of IGF-1R inhibitor, PQ401, on triple negative breast cancer cells
Taylor B. Engdahl, F. Graeme Frost, Amanda J. Schech, Samantha L. Elliott
Author Affiliations +
Abstract

Breast cancer currently has a relatively high survival rate, in part due to the prevalence of effective hormone therapies. However, one breast cancer subtype - triple negative breast cancer (TNBC) - has no targeted therapies available. Furthermore, even subtypes of breast cancer with effective therapies available see dramatic decreases in survival rate upon metastasis. IGFR is an upstream activator of the many different cellular growth and migration pathways, and previously studied inhibitors of IGF-1R have shown efficacy in breast cancer. In this study, we tested PQ401, an IGF-1R inhibitor, in MDA-MB-231 cells to determine the compound's effects on cell viability and migration potential. We determined that the EC50 of PQ401 in MDA-MB-231 cells was 1.95 µM, and that treating cells with 2.5 µM PQ401 significantly decreased cellular motility. This study demonstrates that PQ401 not only decreases cell viability, but also migration in a TNBC cell line.

Copyright Beta Beta Beta Biological Society
Taylor B. Engdahl, F. Graeme Frost, Amanda J. Schech, and Samantha L. Elliott "Viability and migratory effects of IGF-1R inhibitor, PQ401, on triple negative breast cancer cells," BIOS 90(1), 14-19, (26 October 2019). https://doi.org/10.1893/0005-3155-90.1.14
Received: 1 November 2017; Accepted: 2 May 2018; Published: 26 October 2019
JOURNAL ARTICLE
6 PAGES


Share
SHARE
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top